Intérêt des faibles doses de rt-PA dans les syndromes inflammatoires et hémorragiques du segment antérieur: étude clinique et revue de la littérature [Treatment of anterior segment fibrinous reactions and hemorrhage with intracameral low dose rt-PA: clinical study and review of the literature].


Autoria(s): Le Rouic J.F.; Behar-Cohen F.; Nghiem M.H.; Renard G.; Chauvaud D.
Data(s)

2000

Resumo

PURPOSE: to evaluate the efficacy and the safety of low dose intraocular tissue plasminogen activator (rt-PA) in the treatment of traumatic hyphema and postoperative fibrinous membrane. METHODS: Six microg to 10 microg of rt-PA was injected into the anterior chamber to treat severe fibrinous postoperative membranes and total traumatic hyphemae. RESULTS: Thirteen eyes of 13 patients were treated. Four cases of traumatic hyphema and 9 cases of fibrinous membranes were included. Complete fibrinolysis within 24 hours was observed in 4 cases (30.8%). A partial success was noted in 7 eyes (53.8%). No beneficial effect was observed in two cases of traumatic hyphema associated with intravitreal hemorrhage after penetrating trauma. No side effect attributable to rt-PA occurred. CONCLUSION: Low dose intraocular rt-PA appears to be safe and effective in the treatment of postoperative fibrinous membrane and endocular hemorrhage limited to the anterior chamber.

Identificador

https://serval.unil.ch/?id=serval:BIB_2EDC36E2E0FE

isbn:0181-5512 (Print)

pmid:11139689

http://my.unil.ch/serval/document/BIB_2EDC36E2E0FE.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_2EDC36E2E0FE7

isiid:000166499600002

doi:

Idioma(s)

fr

Direitos

info:eu-repo/semantics/openAccess

Fonte

Journal Français D'ophtalmologie, vol. 23, no. 10, pp. 977-983

Palavras-Chave #Adolescent; Adult; Aged; Child; Eye Injuries/drug therapy; Female; Fibrin/secretion; Fibrinolytic Agents/therapeutic use; Humans; Hyphema/drug therapy; Inflammation/drug therapy; Inflammation/etiology; Male; Middle Aged; Ophthalmologic Surgical Procedures; Postoperative Complications/drug therapy; Recombinant Proteins/therapeutic use; Tissue Plasminogen Activator/therapeutic use
Tipo

info:eu-repo/semantics/review

article